Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | BAD | Q92934 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1044992 | 0.93 | BCL2L1 (0.50) | BCL2L1BADALDH1A1MEN1KMT2A | |
| SCHEMBL19249411 | 0.91 | BCL2L1 (0.48) | BCL2L1BADALDH1A1MEN1KMT2A | |
| SCHEMBL30777455 | 0.89 | BCL2L1 (0.45) | BCL2L1BADALDH1A1MEN1KMT2A | |
| SCHEMBL1616679 | 0.89 | BCL2L1 (0.45) | BCL2L1BADALDH1A1MEN1KMT2A | |
| SCHEMBL3453076 | 0.77 | BCL2L1 (0.43) | BCL2L1BADALDH1A1MEN1KMT2A | |
| SCHEMBL3453685 | 0.74 | ALDH1A1 (0.43) | BCL2L1BADALDH1A1MEN1KMT2A | |
| Dimethylamine SCHEMBL6542165 | 0.73 | BCL2L1 (0.50) | BCL2L1BADALDH1A1MEN1KMT2A | |
| SCHEMBL9136887 | 0.73 | BCL2L1 (0.50) | BCL2L1BADALDH1A1MEN1KMT2A | |
| SCHEMBL231793 | 0.73 | BCL2L1 (0.45) | BCL2L1BADALDH1A1MEN1KMT2A | |
| SCHEMBL19729202 | 0.72 | L3MBTL1 (0.39) | BCL2L1BADALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1052982-A4 | AMINOTETRALINS AS 5-HT 1D$g(a)? AGONISTS | LILLY CO ELI (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20020065312-A1 | Aminotetralins as 5-HT1Dalpha agonists | SCHAUS JOHN M (US) | 2002-05-30 | — | — | US | disclosed |
| US-6355674-B1 | PSYCHOLOGICAL DISORDERS; ANTISEROTONINE AGENTS | ELI LILLY AND COMPANY | 2002-03-12 | — | — | US | disclosed |
| EP-1052982-A1 | AMINOTETRALINS AS 5-HT 1D$g(a)? AGONISTS | ELI LILLY AND COMPANY (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-1998048786-A1 | AMINOTETRALINS AS 5-HT1Dα AGONISTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065312-A1 | Aminotetralins as 5-HT1Dalpha agonists | HTR1D, HTR1A, HTR1E | BCL2L1 3393/4885BAD 1201/4885ALDH1A1 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.